We are live on ! Find out more
NBSE

NeuBase Therapeutics, Inc. Common Stock

Delisted

NBSE was delisted on the 10th of May, 2024.

64 hedge funds and large institutions have $18.4M invested in NeuBase Therapeutics, Inc. Common Stock in 2015 Q1 according to their latest regulatory filings, with 23 funds opening new positions, 20 increasing their positions, 11 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

193% more call options, than puts

Call options by funds: $2.55M | Put options by funds: $871K

109% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 11

82% more repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 11

21% more funds holding

Funds holding: 5364 (+11)

64% less capital invested

Capital invested by funds: $50.6M → $18.4M (-$32.1M)

Holders
64
Holders Change
+11
Holders Change %
+20.75%
% of All Funds
1.71%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
23
Increased
20
Reduced
11
Closed
11
Calls
$2.55M
Puts
$871K
Net Calls
+$1.68M
Net Calls Change
+$1.19M
Name Holding Trade Value Shares
Change
Change in
Stake
BC
1
Broadfin Capital
New York
$4.51M +$14.7M +4,438 New
Vanguard Group
2
Vanguard Group
Pennsylvania
$1.55M +$399K +121 +9%
BFA
3
BlackRock Fund Advisors
California
$1.53M -$75.9K -23 -2%
BBA
4
Baker Bros. Advisors
New York
$941K +$3.06M +926 New
TI
5
Turner Investments
Pennsylvania
$727K +$2.36M +716 New
State Street
6
State Street
Massachusetts
$655K +$320K +97 +18%
California Public Employees Retirement System
7
California Public Employees Retirement System
California
$608K
Northern Trust
8
Northern Trust
Illinois
$597K +$185K +56 +11%
KCM
9
Knoll Capital Management
Florida
$521K +$1.69M +513 New
SM
10
Sabby Management
Florida
$496K +$1.2M +363 +290%
BIT
11
BlackRock Institutional Trust
California
$484K +$6.6K +2 +0.4%
SFM
12
Sphera Funds Management
Israel
$476K +$1.55M +469 New
AllianceBernstein
13
AllianceBernstein
Tennessee
$455K +$532K +161 +56%
DBG
14
De Burlo Group
Massachusetts
$409K +$1.33M +403 New
Geode Capital Management
15
Geode Capital Management
Massachusetts
$329K +$139K +42 +15%
Millennium Management
16
Millennium Management
New York
$272K -$5.95M -1,802 -87%
SIP
17
Stoneridge Investment Partners
Pennsylvania
$233K +$446K +135 +144%
Bank of New York Mellon
18
Bank of New York Mellon
New York
$231K -$56.1K -17 -7%
GBA
19
Garrison Bradford & Associates
New York
$217K
HF
20
Hoxton Financial
West Virginia
$209K +$677K +205 +20,500%
EIM
21
Essex Investment Management
Massachusetts
$190K +$617K +187 New
TCIM
22
TIAA CREF Investment Management
New York
$185K
PNC Financial Services Group
23
PNC Financial Services Group
Pennsylvania
$176K
Susquehanna International Group
24
Susquehanna International Group
Pennsylvania
$166K +$178K +54 +50%
BIM
25
BlackRock Investment Management
Delaware
$158K +$9.9K +3 +2%

NBSE Hedge Fund Activity: Q1 2015 in Review

64 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in NeuBase Therapeutics, Inc. Common Stock (NBSE) for Q1 2015, worth a combined $18.4M — down 64% from $50.6M a quarter earlier.

Buyers outnumbered sellers: 23 funds opened new NBSE positions and 11 closed out — a net gain of 12 holders — while 20 added to existing stakes and 11 trimmed.

The largest buyer was Broadfin Capital, opening a new position worth an estimated $14.7M. The largest seller was Visium Asset Management, exiting entirely with an estimated $8.62M sold.

  • 64 institutional investors held NeuBase Therapeutics, Inc. Common Stock (NBSE) as of Q1 2015, up from 53 in Q4 2014.
  • Funds reported $18.4M of NeuBase Therapeutics, Inc. Common Stock stock for Q1 2015, down 64% quarter-over-quarter.
  • 23 funds opened new NeuBase Therapeutics, Inc. Common Stock positions in Q1 2015 and 11 closed out, a net change of +12 holders.
  • The largest NeuBase Therapeutics, Inc. Common Stock buyer in Q1 2015 was Broadfin Capital, an estimated $14.7M added.
  • The largest NeuBase Therapeutics, Inc. Common Stock seller in Q1 2015 was Visium Asset Management, an estimated $8.62M sold.

Based on aggregated 13F filings for Q1 2015.